Skip to main content
Top
Published in: Supportive Care in Cancer 10/2012

01-10-2012 | Original Article

The use of hyperbaric oxygen for treating delayed radiation injuries in gynecologic malignancies: a review of literature and report of radiation injury incidence

Authors: Scott Allen, Chris Kilian, Jenise Phelps, Harry T. Whelan

Published in: Supportive Care in Cancer | Issue 10/2012

Login to get access

Abstract

Purpose

The purposes of this paper are to review the best evidence supporting the use of hyperbaric oxygen therapy (HBOT) in delayed radiation injuries in gynecologic malignancies and report the incidence of radiation injuries at two large medical centers in southeastern Wisconsin.

Methods

A literature search was performed on Google Scholar, PubMed, and Ovid for studies evaluating the use of HBOT radiation cystitis, proctitis, and necrosis. The studies were then reviewed for the highest quality evidence using American Academy of Neurology guidelines. To evaluate radiation injuries, cancer databases at Froedtert Memorial Lutheran Hospital (FMLH) and Aurora St. Luke’s Hospital (ASLH) were accessed.

Results

Several studies support the use of HBOT in treating radiation cystitis, proctitis, and necrosis, with proctitis having the strongest evidence in its favor. The average annual incidence of radiation injury at FMLH was 13.8%. Patients with cervical cancer and vulvar cancer had rates of 23% each. The average annual incidence of radiation injury among gynecologic cancer patients at ASLH was 5.5%.

Conclusions

There is level A evidence for using HBOT to treat radiation proctitis. There is level B evidence for using HBOT to treat radiation cystitis and necrosis. The incidence delayed radiation injuries can be as high as 23%. This has relevance in practice guidelines for the treatment of delayed radiation injuries in gynecologic malignancies.
Literature
1.
go back to reference Marx RE (1983) Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 41:283–288PubMedCrossRef Marx RE (1983) Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 41:283–288PubMedCrossRef
2.
go back to reference Kindwall EP, Whelan HT (2008) Hyperbaric medicine practice, 3rd edn. Best Publishing Company, Flagstaff Kindwall EP, Whelan HT (2008) Hyperbaric medicine practice, 3rd edn. Best Publishing Company, Flagstaff
3.
go back to reference Knighton DR, Silver IA, Hunt TK (1981) Regulation of wound healing angiogenesis: effect of oxygen gradients and inspired oxygen concentrations. Surgery 90:262–270PubMed Knighton DR, Silver IA, Hunt TK (1981) Regulation of wound healing angiogenesis: effect of oxygen gradients and inspired oxygen concentrations. Surgery 90:262–270PubMed
4.
go back to reference Davis JC et al (1979) Hyperbaric oxygen: a new adjunct in the management of radiation necrosis. Arch Otolaryngol 105:58–61PubMedCrossRef Davis JC et al (1979) Hyperbaric oxygen: a new adjunct in the management of radiation necrosis. Arch Otolaryngol 105:58–61PubMedCrossRef
5.
go back to reference Sidik et al (2007) Does hyperbaric oxygen administration decrease side effect and improve quality of life after pelvic radiation? Acta Med Indones 39(4):169–173PubMed Sidik et al (2007) Does hyperbaric oxygen administration decrease side effect and improve quality of life after pelvic radiation? Acta Med Indones 39(4):169–173PubMed
6.
go back to reference Clarke RE, Tenorio LM, Hussey JR et al (2008) Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 72:134–143PubMedCrossRef Clarke RE, Tenorio LM, Hussey JR et al (2008) Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 72:134–143PubMedCrossRef
7.
go back to reference Ophoven V et al (2006) Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol 176:1442–1446PubMedCrossRef Ophoven V et al (2006) Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol 176:1442–1446PubMedCrossRef
9.
go back to reference Bevers RFM, Bakker DJ, Kurth KH (1995) Hyperbaric oxygen treatment for hemorrhagic radiation cystitis. Lancet 346:803–805PubMedCrossRef Bevers RFM, Bakker DJ, Kurth KH (1995) Hyperbaric oxygen treatment for hemorrhagic radiation cystitis. Lancet 346:803–805PubMedCrossRef
10.
go back to reference Chong et al (2005) Early hyperbaric oxygen therapy improves outcomes for radiation-induced hemorrhagic cystitis. Urology 65:649–653PubMedCrossRef Chong et al (2005) Early hyperbaric oxygen therapy improves outcomes for radiation-induced hemorrhagic cystitis. Urology 65:649–653PubMedCrossRef
11.
go back to reference Weir G (2009) Hyperbaric oxygen therapy for complication of radiotherapy. Wound Healing South Afr 2:60–62 Weir G (2009) Hyperbaric oxygen therapy for complication of radiotherapy. Wound Healing South Afr 2:60–62
13.
go back to reference Warren DC, Feehan P, Slade JB, Cianci PE (1997) Chronic radiation proctitis treated with hyperbaric oxygen. Undersea Hyperb Med 24(3):181–184PubMed Warren DC, Feehan P, Slade JB, Cianci PE (1997) Chronic radiation proctitis treated with hyperbaric oxygen. Undersea Hyperb Med 24(3):181–184PubMed
14.
go back to reference Lee HC, Liu CS, Chiao C, Lin SN (1994) Hyperbaric oxygen therapy in hemorrhagic cystitis: a report of 20 cases. Undersea Hyperb Med 21(3):321–327PubMed Lee HC, Liu CS, Chiao C, Lin SN (1994) Hyperbaric oxygen therapy in hemorrhagic cystitis: a report of 20 cases. Undersea Hyperb Med 21(3):321–327PubMed
15.
go back to reference Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN (1998) Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long term followup. J Urol 160:731–733PubMedCrossRef Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN (1998) Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long term followup. J Urol 160:731–733PubMedCrossRef
16.
go back to reference Williams JA, Clarke D, Dennis WA, Dennis E, Smith ST (1992) The treatment of pelvic soft tissue radiation necrosis with hyperbaric oxygen. Am J Obstet Gynecol 167:412–416PubMed Williams JA, Clarke D, Dennis WA, Dennis E, Smith ST (1992) The treatment of pelvic soft tissue radiation necrosis with hyperbaric oxygen. Am J Obstet Gynecol 167:412–416PubMed
17.
go back to reference Feldmeier JJ, Hampson NB (2002) A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med 29:4–30PubMed Feldmeier JJ, Hampson NB (2002) A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med 29:4–30PubMed
18.
go back to reference Fink D, Chetty N, Lehm JP, Marsden DE, Hacker NF (2006) Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. Int J Gynecol Cancer 16:638–642PubMedCrossRef Fink D, Chetty N, Lehm JP, Marsden DE, Hacker NF (2006) Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. Int J Gynecol Cancer 16:638–642PubMedCrossRef
Metadata
Title
The use of hyperbaric oxygen for treating delayed radiation injuries in gynecologic malignancies: a review of literature and report of radiation injury incidence
Authors
Scott Allen
Chris Kilian
Jenise Phelps
Harry T. Whelan
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1379-x

Other articles of this Issue 10/2012

Supportive Care in Cancer 10/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine